ALREX Drug Patent Profile

✉ Email this page to a colleague

When do Alrex patents expire, and what generic alternatives are available?

Alrex is a drug marketed by Bausch And Lomb and is included in one NDA.

The generic ingredient in ALREX is loteprednol etabonate. There are ten drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the loteprednol etabonate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Alrex

A generic version of ALREX was approved as loteprednol etabonate by SENTISS on April 17^th, 2019.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for ALREX?
What are the global sales for ALREX?
What is Average Wholesale Price for ALREX?

Summary for ALREX

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	63
Patent Applications:	4,390
Drug Prices:	Drug price information for ALREX
Drug Sales Revenues:	Drug sales revenues for ALREX
What excipients (inactive ingredients) are in ALREX?	ALREX excipients list
DailyMed Link:	ALREX at DailyMed

Drug patent expirations by year for ALREX

Pharmacology for ALREX

Drug Class	Corticosteroid
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

US Patents and Regulatory Information for ALREX

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch And Lomb	ALREX	loteprednol etabonate	SUSPENSION/DROPS;OPHTHALMIC	020803-001	Mar 9, 1998	AB	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for ALREX

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bausch And Lomb	ALREX	loteprednol etabonate	SUSPENSION/DROPS;OPHTHALMIC	020803-001	Mar 9, 1998	⤷ Sign Up	⤷ Sign Up
Bausch And Lomb	ALREX	loteprednol etabonate	SUSPENSION/DROPS;OPHTHALMIC	020803-001	Mar 9, 1998	⤷ Sign Up	⤷ Sign Up
Bausch And Lomb	ALREX	loteprednol etabonate	SUSPENSION/DROPS;OPHTHALMIC	020803-001	Mar 9, 1998	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for ALREX

See the table below for patents covering ALREX around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Australia	697617		⤷ Sign Up
Philippines	25874	Soft steroids having anti-inflammatory activity	⤷ Sign Up
World Intellectual Property Organization (WIPO)	9511669		⤷ Sign Up
Australia	7983594		⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

AI Research Assistant

Questions you can ask:

Summary for ALREX

Pharmacology for ALREX

Make Better Decisions: Try a trial or see plans & pricing